Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 87, Issue 5, Pages 558-562Publisher
WILEY
DOI: 10.1038/clpt.2009.232
Keywords
-
Categories
Funding
- Research Grants Council of the Hong Kong Special Administrative Region, China [CUHK 4472/06M]
Ask authors/readers for more resources
The ATP-binding cassette G2 (ABCG2) c.421C>A (rs2231142) polymorphism influences the pharmacokinetics of rosuvastatin. We examined whether this polymorphism influences the low-density lipoprotein cholesterol (LDL-C)lowering efficacy of the drug. In 305 Chinese patients with hypercholesterolemia who were treated with rosuvastatin at a dosage of 10 mg daily, the c.421A variant was found to be significantly associated with greater reduction in LDL-C level, in a gene-dose-dependent manner. As compared with subjects with the c.421CC genotype, those with the c.421AA genotype showed a 6.9% greater reduction in LDL-C level, which would be equivalent to the effect obtained by doubling the dose of rosuvastatin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available